甲磺酸酚妥拉明(Phentolamine Mesylate) - 药物靶点：adrenergic receptor_在研适应症：瞳孔散大，麻醉，勃起功能障碍_专利_临床

概要

基本信息

药物类型

小分子化药

别名

2-(N-(m-hydroxyphenyl)-p-toluidinomethyl)imidazoline、Nyxol、phentolamine

+ [22]

靶点

adrenergic receptor

作用方式

拮抗剂

作用机制

adrenergic receptor拮抗剂(肾上腺素能受体家族拮抗剂)

治疗领域

神经系统疾病眼部疾病泌尿生殖系统疾病+ [1]

在研适应症

瞳孔散大麻醉勃起功能障碍+ [2]

非在研适应症

失明开角型青光眼视力低下

原研机构

Novartis Pharma AG

在研机构

Septodont Holding SASFamy Life Sciences Pvt Ltd.

Opus Genetics, Inc.

+ [2]

非在研机构

北京福瑞康正医药技术研究所

Novartis Pharmaceuticals Corp.

权益机构

Opus Genetics, Inc.

最高研发阶段批准上市

首次获批日期

美国 (1952-01-30),

麻醉

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)

登录后查看时间轴

结构/序列

分子式C18H23N3O4S

InChIKeyOGIYDFVHFQEFKQ-UHFFFAOYSA-N

CAS号65-28-1

关联

52

项与甲磺酸酚妥拉明相关的临床试验

NCT07140783

/ Recruiting临床3期

RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-MASKED STUDY OF THE SAFETY AND EFFICACY OF POS (0.75% PHENTOLAMINE OPHTHALMIC SOLUTION) IN PARTICIPANTS WITH PREVIOUS KERATOREFRACTIVE SURGERY WITH DECREASED VISUAL ACUITY UNDER MESOPIC CONDITIONS

The goal of this clinical trial is to learn if Phentolamine Ophthalmic Solution works to treat adults that have had keratorefractive surgery and have decreased visual acuity under mesopic conditions. It will also learn about the safety of Phentolamine Ophthalmic Solution. The main questions it aims to answer are:
Researchers will compare Phentolamine Ophthalmic Solution to a placebo (a look-alike substance that contains no drug) to see if Phentolamine Ophthalmic Solution works to improve vision in low light conditions.
Participants will:
Take Phentolamine Ophthalmic Solution or a placebo drop every day for 2 weeks Visit the clinic once every week for 2 weeks for checkups and tests Keep a diary of when they instill the study medication each evening

开始日期2025-09-02

申办/合作机构

Opus Genetics, Inc.

NCT06787066

/ Recruiting早期临床1期IIT

Sympathetic Vascular Transduction Across the Menopause Transition: Contributing Mechanisms

The investigators aim to assess the interactions between the sympathetic nervous system and the vasculature in women across the menopause transition to better understand why aging women have a higher risk of cardiovascular disease.

开始日期2025-07-10

申办/合作机构

University of Missouri

NCT05448807

/ Recruiting临床3期IIT

A Randomized Effectiveness of Phentolamine Mesylate as a Reversing Agent for Local Anesthesia in Decreasing Self- Inflicted Soft Tissue Trauma Following Local Anaesthesia Injection for Dental Procedure in Children: Randomized Clinical Trial

Local anaesthesia is considered one of the most alarming and non-comfortable dental procedures for children. This goes back to the persisting effect of the local anaesthesia after finishing dental procedures. The effect of Local anaesthesia can last from 3 to 5 hours due to the presence of vasoconstrictor. The U.S Food and Drug Administration (FDA approved the use of phentolamine mesylate (Oraverse) in May 2008 to be used as a drug in reversing the numbing effect of Local anaesthesia by decreasing the time needed to restore the normal functions of the mouth

开始日期2025-07-05

申办/合作机构

Cairo University

100 项与甲磺酸酚妥拉明相关的临床结果

登录后查看更多信息

100 项与甲磺酸酚妥拉明相关的转化医学

登录后查看更多信息

100 项与甲磺酸酚妥拉明相关的专利（医药）

登录后查看更多信息

11,367

项与甲磺酸酚妥拉明相关的文献（医药）

2026-01-01·EUROPEAN JOURNAL OF PHARMACOLOGY

Echinatin as a multimodal modulator of monoaminergic system: Preclinical evidence for antidepressant-like activity

Article

作者: Türkoğlu Sağlık, Gizem ; Can, Özgür Devrim

Mounting evidence highlights flavonoids as multitarget candidates for central nervous system disorders because they can cross the blood-brain barrier and modulate diverse neurotransmitter pathways. Echinatin, a chalcone-type flavonoid from Glycyrrhiza species, has not previously been evaluated in behavioral models relevant to mood disorders. Here, we examined whether echinatin exerts antidepressant-like effects in validated rodent tests and explored the underlying monoaminergic mechanisms using pharmacological manipulations. Male BALB/c mice received echinatin (20 or 30 mg/kg), fluoxetine (10 mg/kg) or reboxetine (20 mg/kg). Antidepressant-like activity was assessed in the tail-suspension and modified forced-swimming tests, while motor performance was evaluated with the Rota-rod and the activity-meter. To delineate monoaminergic involvement, mice were pretreated with p-chlorophenylalanine (PCPA; serotonin synthesis inhibitor), α-methyl-p-tyrosine (AMPT; catecholamine synthesis inhibitor), WAY-100635 (serotonin 5-HT1A receptor antagonist), phentolamine (α-adrenoceptor antagonist), propranolol (β-adrenoceptor antagonist), SCH-23390 (dopamine D1 receptor antagonist), sulpiride (dopamine D2/D3 receptor antagonist) or ketanserin (serotonin 5-HT2A/5-HT2C receptor antagonist). Echinatin at 30 mg/kg markedly reduced immobility in both behavioral tests, producing effects comparable to reference antidepressants, without affecting locomotor activity or motor coordination. The anti-immobility effect was reversed by serotonergic (PCPA, WAY-100635), noradrenergic (AMPT, phentolamine, propranolol) and dopaminergic (SCH-23390, sulpiride) interventions, but was not altered by ketanserin. These findings provide the first pharmacological evidence that echinatin elicits antidepressant-like effects through broad monoaminergic modulation and support its further evaluation as a potential lead compound for antidepressant drug development.

2026-01-01·FITOTERAPIA

Antimicrobial activity of naturally occurring tuliposides and tulipalins, and synthetic tulipalin analogs against bacterial and yeast strains

Article

作者: Nomura, Taiji ; Kato, Yasuo

Glucose esters of α-methylene-γ-hydroxybutyrates known as tuliposides (Pos) are accumulated in tulip and are enzymatically converted to bioactive tulipalins (Pa) by a carboxylesterase, a tuliposide-converting enzyme. Herein, we evaluated the antibacterial and anti-yeast activities of naturally occurring variants of Pos and Pa, along with synthetic Pa analogs, including ring-opened hydroxy acids of Pa (PaA/B-acids) and their methyl esters, predicted PaB degradation products, and ring-expanded analogs of Pa, by determining their half-maximal inhibitory concentration values through turbidimetric assays. To enhance compound stability during the assay, we developed a modified minimal medium. PaA-forming (A-type) Pos (6-PosA, 1-PosA, PosD, PosG, and PosK-M) and PaA showed little or no antibacterial activity, whereas PaB-forming (B-type) Pos (6-PosB and PosF) and PaB showed markedly higher activity. Among the PaA/B-acids and methyl esters, only PaB-acid methyl ester showed activity, likely because of its ability to form active PaB. All tested PaB degradation products and their analogs exhibited no antibacterial activity. The activity trend of the ring-expanded analogs of PaA/B was similar to that of A- or B-type analogs. In anti-yeast assays, both PaA and PaB displayed weak and comparable activities, suggesting different modes of action against bacteria and yeast. These results enhance our understanding of the natural roles and potential applications of Pos, Pa, and their analogs as antimicrobial agents.

2025-11-01·POULTRY SCIENCE

Effects of pectic oligosaccharide on growth performance, organ indexes and intestinal health in broilers exposed to aflatoxin B1

Article

作者: Ye, Hui ; Zhang, Changming ; Wang, Weiwei ; Qin, Yongzhi ; Zuo, Jianjun ; Dong, Zemin ; Cao, Qingyun ; Ye, Zhengqi ; Zhang, Haijun ; Xian, Meitian

This study aimed at investigating the influences of pectic oligosaccharide (POS) on growth performance, organ indexes and intestinal health in broilers exposed to aflatoxin B₁ (AFB₁). In vitro experiment was conducted to assess reactive oxygen species (ROS)-scavenging ability of POS. In vivo experiment was then implemented by allocating 320 one-day-old yellow-feathered broilers to 4 groups (8 replicates/group), according to a 2 × 2 factorial arrangement with POS addition (0 or 400 mg/kg) and AFB₁ exposure (with or without) as the two factors. All parameters were determined on d 21. The results revealed an in vitro ability of POS to scavenge ROS. AFB₁ exposure tended to decrease (P < 0.10) average daily gain (ADG) and average daily feed intake (ADFI), as well as caused abnormities in liver, thymus and bursal indexes. It also elevated (P < 0.05) intestinal ROS and malondialdehyde contents but reduced (P < 0.05) intestinal catalase and glutathione peroxidase activities, as well as caused intestinal injuries including the decreasing trends (P < 0.10) of ileal villus height:crypt depth ratio and the relative mRNA expression of claudin-1 together with the increasing trend (P < 0.10) of serum diamine oxidase (DAO) activity. POS addition tended to elevate (P < 0.10) ADG and ADFI, as well as mitigated AFB₁-induced elevation (P < 0.10) in spleen index and reduction (P < 0.05) of bursal index. Moreover, POS addition tended to enhance (P < 0.10) ileal total antioxidant capacity in AFB₁-exposed broilers. Besides, POS addition lowered (P < 0.05) ROS level and increased (P < 0.05) glutathione content in ileum, as well as showed a tendency (P < 0.10) to elevate ileal claudin-1 expression and decrease serum DAO activity of broilers regardless of AFB₁ exposure. Collectively, supplemental POS benefited growth performance and organ indexes of broilers exposed to AFB₁, which could attribute to its ability to ameliorate intestinal redox state and integrity. These findings underscore a potential of POS to attenuate the detriments of AFB₁ contamination in diets.

207

项与甲磺酸酚妥拉明相关的新闻（医药）

2025-12-09

·GlobeNewswire-Health Care

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Initial favorable safety profile demonstrated in OPGx-BEST1 clinical trialRESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the Independent Data Monitoring Committee (IDMC) issued a positive recommendation to continue as planned in the Company’s Phase 1/2 BEST1 clinical trial (BIRD-1), which is a multi-center, adaptive, open-label, dose-exploring study evaluating OPGx-BEST1 in participants with Best disease. The IDMC overseeing the trial completed its pre-specified safety review of the one-month data from the sentinel participant and recommended advancing enrollment and dosing of additional participants in the trial, without modification. “We are thrilled with this outcome from the first participant, whose encouraging safety results at one month enable us to proceed with dosing the next four participants in our BEST1 Phase 1/2 trial,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. “The IDMC’s safety review and recommendation to continue the trial reinforces our confidence as we advance this program. BEST1-associated retinal diseases constitute a substantial unmet medical need, and this progress with OPGx-BEST1 represents an important step toward potentially preserving and restoring visual function for patients with Best disease.” About OPGx-BEST1 and the Phase 1/2 Trial OPGx-BEST1 leverages Opus Genetics’ proprietary AAV-based gene therapy platform, designed to deliver a functional copy of the BEST1 gene directly to the retinal pigment epithelium (RPE) cells where the defective gene resides. The program builds on extensive preclinical work demonstrating restoration of BEST1 protein expression and improved retinal function in relevant disease models. The multi-center, adaptive, open-label, dose-exploring study, known as BIRD-1, will evaluate the safety, tolerability, and preliminary efficacy of OPGx-BEST1 in participants with Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB). Treatment will be administered via a single subretinal injection in one eye of each participant with two dosing cohorts. The trial will also explore biological activity through functional and anatomical endpoints, including changes in visual function and retinal structure. About BEST1 Inherited Retinal Disease Best disease, or vitelliform macular dystrophy, is a rare inherited retinal condition caused by mutations in the BEST1 gene, leading to impaired retinal pigment epithelium (RPE) function, progressive vision loss, and, in some cases, blindness. The BEST1 gene is responsible for providing instructions to produce bestrophin, a protein that acts as a channel to manage the movement of charged chloride ions in and out of retinal cells. Variants (mutations) in the BEST1 gene, as well as the PRPH2 gene, can result in the formation of abnormally shaped channels that cannot properly control chloride flow. BEST1 plays a key role in the RPE, which is essential for healthy vision, and such mutations can lead to BEST1-related inherited retinal diseases (bestrophinopathies). These rare conditions affect an estimated 9,000 patients across the United States and can lead to progressive vision loss and blindness. About Opus Genetics Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, RDH12, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, an approved small-molecule therapy for pharmacologically induced mydriasis, with additional indications in late-stage development for presbyopia and low-light visual disturbances following keratorefractive surgery. The Company is based in Research Triangle Park, NC. For more information, please visit www.opusgtx.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements related to the clinical development, clinical results, preclinical data, and future plans for Phentolamine Ophthalmic Solution 0.75%, OPGx-LCA5, OPGx-BEST1, RDH12, and earlier stage programs, and expectations regarding us, our business prospects, and our results of operations and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “strive,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise. Contacts InvestorsJenny KobinRemy BernardaIR Advisory Solutionsir@opusgtx.com MediaKimberly HaKKH Advisors917-291-5744kimberly.ha@kkhadvisors.com Source: Opus Genetics, Inc.

基因疗法临床研究临床结果

2025-11-15

·GlobeNewswire-Health Care

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Emerging gene therapy administered through a one-time subretinal injection marks a major milestone for the inherited retinal disease community Initial data expected in Q1 2026 Nov. 13, 2025 -- Opus Genetics, (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the first participant has been dosed in the Company’s OPGx-BEST1 Phase 1/2 clinical trial for Best disease (BEST1). Best disease, or vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by mutations in the BEST1 gene, leading to progressive vision loss and, in some cases, blindness. OPGx-BEST1 is an emerging gene therapy administered through a one-time subretinal injection designed to restore function to the retinal pigment epithelium (RPE) cells affected by mutations in the BEST1 gene. The Phase 1/2 trial is being conducted by Dr. Mark Pennesi of the Retina Foundation of the Southwest and the surgical team of Drs. Kenneth Fan and Charles Wykoff at Retina Consultants of Texas. “Dosing the first participant in our OPGx-BEST1 program is a historic moment for the BEST disease community and for our team at Opus,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. “This milestone reinforces our mission to develop one-time gene therapies for inherited retinal diseases that previously had no treatment options. It’s a privilege to collaborate with leaders in the field like Drs. Pennesi, Fan, and Wykoff. We are deeply thankful to the Retina Foundation of the Southwest, Retina Consultants of Texas, and most importantly, the patients and families who place their trust in us. Together, we are striving to build a future where no one loses their sight to inherited retinal disease.” “This milestone highlights the significant progress being made in ophthalmic gene therapy and the potential power of collaboration between industry and academia to bring new hope to families affected by inherited retinal diseases,” said Dr. Mark Pennesi, Director of the Inherited Retinal Degeneration Clinic at the Retina Foundation of the Southwest. “For patients with Best disease, this represents an important step toward potentially preserving and restoring vision.” “The successful dosing of the first patient underscores both the potential promise of gene therapy in ophthalmology and the dedication of the entire community working to make these treatments a reality,” said Dr. Charles Wykoff, Surgical Retina Specialist and Ophthalmologist at the Retina Consultants of Texas. “It’s inspiring to see years of scientific progress translate into potentially meaningful advances for patients and families.” OPGx-BEST1 leverages Opus Genetics’ proprietary AAV-based gene therapy platform, designed to deliver a functional copy of the BEST1 gene directly to the retinal pigment epithelium (RPE) cells where the defective gene resides. The program builds on extensive preclinical work demonstrating restoration of BEST1 protein expression and improved retinal function in relevant disease models. The multi-center, adaptive, open-label, dose-exploring study, known as BIRD-1, will evaluate the safety, tolerability, and preliminary efficacy of OPGx-BEST1 in participants with Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB). Treatment will be administered via a single subretinal injection in one eye of each participant with two dosing cohorts. The trial will also explore biological activity through functional and anatomical endpoints, including changes in visual function and retinal structure. Initial data from the trial is expected in the first quarter of 2026. The BEST1 gene is responsible for providing instructions to produce bestrophin, a protein that acts as a channel to manage the movement of charged chloride ions in and out of retinal cells. Variants (mutations) in the BEST1 gene, as well as the PRPH2 gene, can result in the formation of abnormally shaped channels that cannot properly control chloride flow. BEST1 plays a key role in the retinal pigment epithelium (RPE), which is essential for healthy vision, and such mutations can lead to BEST1-related inherited retinal diseases (bestrophinopathies). These rare conditions affect an estimated 9,000 patients across the United States and can lead to progressive vision loss and blindness. Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, RDH12, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, an approved small-molecule therapy for pharmacologically induced mydriasis, with additional indications in late-stage development for presbyopia and low-light visual disturbances following keratorefractive surgery. The Company is based in Research Triangle Park, NC. The content above comes from the network. if any infringement, please contact us to modify.

基因疗法临床研究

2025-11-14

·RP之光爱心家园

Opus Genetics宣布OPGx-BEST1基因疗法1/2期临床试验首例受试者完成给药

2025年11月14日 Opus Genetics是一家临床阶段的生物制药公司，致力于开发基因疗法，以恢复患有遗传性视网膜疾病 (IRD) 患者的视力并预防失明。该公司今天宣布，其针对 Best 病 (BEST1) 的 OPGx-BEST1 1/2 期临床试验的首位受试者已接受给药。 BEST病，又称卵黄样黄斑营养不良，是一种罕见的遗传性视网膜疾病，由BEST1基因突变引起黄斑变性，导致进行性视力丧失，在某些情况下甚至会导致失明。OPGx-BEST1是一种新兴的基因疗法，通过一次性视网膜下注射给药，旨在恢复受BEST1基因突变影响的视网膜色素上皮（RPE）细胞的功能。 1/2 期试验由美国西南视网膜基金会的 Mark Pennesi 博士和德克萨斯州视网膜顾问公司的 Kenneth Fan 博士和 Charles Wykoff 博士的外科团队进行。 Opus Genetics首席执行官George Magrath博士表示：“为我们的OPGx-BEST1项目首位受试者进行给药，对于BEST疾病群体和我们Opus团队而言，都是一个历史性的时刻，这一里程碑巩固了我们为以往无药可医的遗传性视网膜疾病开发一次性基因疗法的使命。能够与Pennesi博士、Fan博士和Wykoff博士等该领域的领军人物合作，我们深感荣幸。我们衷心感谢西南视网膜基金会、德克萨斯州视网膜顾问中心，以及最重要的，信任我们的患者及其家人。我们将携手努力，共创一个不再有人因遗传性视网膜疾病而失明的未来。” 西南视网膜基金会遗传性视网膜变性诊所主任马克·佩内西博士表示：“这一里程碑凸显了眼科基因治疗领域取得的重大进展，以及产学研合作为受遗传性视网膜疾病影响的家庭带来新希望的巨大潜力，对于患有Best disease 的患者而言，这代表着在保护和恢复视力方面迈出了重要一步。” 德克萨斯州视网膜顾问中心的视网膜外科专家兼眼科医生查尔斯·威科夫博士表示：“首例患者成功接受基因治疗，不仅凸显了基因疗法在眼科领域的巨大潜力，也展现了整个致力于将这些疗法变为现实的团队的奉献精神，看到多年的科学进步转化为可能对患者及其家庭产生重大影响的成果，令人倍感鼓舞。” 关于 OPGx-BEST1 和 1/2 期试验 OPGx-BEST1 利用 Opus Genetics 专有的基于腺相关病毒 (AAV) 的基因疗法平台，旨在将功能性 BEST1 基因拷贝直接递送至视网膜色素上皮 (RPE) 细胞，该细胞正是缺陷基因所在之处。该项目建立在大量的临床前研究之上，这些研究表明，在相关疾病模型中，该疗法能够恢复 BEST1 蛋白的表达并改善视网膜功能。这项名为BIRD-1的多中心、适应性、开放标签、剂量探索性研究将评估OPGx-BEST1在患有Best卵黄样黄斑营养不良（BVMD）或常染色体隐性遗传性Bestrophin病（ARB）患者中的安全性、耐受性和初步疗效。治疗将通过单次视网膜下注射的方式进行，每位受试者仅一只眼睛接受治疗，并分为两个剂量组。该试验还将通过功能性和解剖学终点来探索其生物活性，包括视觉功能和视网膜结构的变化。该试验的初步数据预计将于2026年第一季度公布。关于BEST1遗传性视网膜疾病 BEST1基因负责为生成bestrophin蛋白提供指令，该蛋白作为一种通道，调控视网膜细胞内外带电氯离子的流动。BEST1基因或PRPH2基因的变异（突变）会导致通道结构异常，从而无法正常控制氯离子流量。BEST1在视网膜色素上皮（RPE）中发挥关键作用，而RPE对维持健康视力至关重要。此类突变可能引发BEST1相关的遗传性视网膜疾病（bestrophinopathies）。这类罕见病在美国约影响9,000名患者，可导致进行性视力下降甚至失明。关于 Opus Genetics Opus Genetics是一家临床阶段的生物制药公司，致力于开发基因疗法，以恢复患有遗传性视网膜疾病（IRD）患者的视力并预防失明。公司正在开发持久有效的单次治疗方案，旨在解决严重视网膜疾病的根本遗传病因。公司目前在研的七项基于腺相关病毒（AAV）的项目包括：针对LCA5相关突变的OPGx-LCA5和针对BEST1相关视网膜变性的OPGx-BEST1，以及其他靶向RHO、RDH12和MERTK的候选药物。Opus Genetics还在推进酚妥拉明滴眼液0.75%的研发，这是一种已获批准的小分子药物，用于治疗药物诱导的瞳孔散大，目前正处于后期开发阶段，用于治疗老花眼和角膜屈光手术后的弱光视觉障碍。公司总部位于北卡罗来纳州的研究三角园区。更多信息，请访问www.opusgtx.com。声明：本文旨在传递遗传性视网膜疾病研究和治疗前沿信息。文章内容仅代表作者观点，并不代表RP之光爱心家园立场，亦不构成医疗指导，如有需求请咨询专业人士或前往正规医院就诊。

基因疗法临床研究临床结果

100 项与甲磺酸酚妥拉明相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00509	甲磺酸酚妥拉明	V03AB36 C04AB01	DB00692

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
瞳孔散大	美国	Famy Life Sciences Pvt Ltd.	2023-09-25
勃起功能障碍	中国	上海复旦复华药业有限公司	1989-01-01
麻醉	美国	Novartis Pharmaceuticals Corp.	1952-01-30

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
夜盲症	临床3期	美国	Opus Genetics, Inc.	2023-04-27
老花眼	临床3期	美国	Opus Genetics, Inc.	2022-12-22
视力低下	临床3期	美国	Opus Genetics, Inc.	2020-12-30
开角型青光眼	临床2期	美国	Opus Genetics, Inc.	2019-05-28
失明	临床2期	美国	Opus Genetics, Inc.	2007-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06542497 (VEGA-3, Company_Website) 人工标引	临床3期	老花眼	545	Phentolamine Ophthalmic Solution 0.75%	淵鹹鹹廠顧鑰餘願淵壓(構簾範鹽鹹蓋窪夢觸襯) = 衊簾顧憲衊艱觸範鏇遞獵繭構衊蓋蓋觸遞鏇衊 (衊齋簾膚膚繭夢積選蓋 ) 达到更多	积极	2025-06-26
				Placebo	淵鹹鹹廠顧鑰餘願淵壓(構簾範鹽鹹蓋窪夢觸襯) = 鏇壓齋窪構餘艱遞齋膚獵繭構衊蓋蓋觸遞鏇衊 (衊齋簾膚膚繭夢積選蓋 ) 达到更多
NCT05646719 (VEGA-2, CTgov)	临床3期	老花眼	333	Phentolamine Opthalmic Solution 0.75%+Low dose pilocarpine (Nyxol + Low Dose Pilocarpine)	窪齋選餘鹹壓繭獵觸築 = 艱衊淵觸鹽齋壓築膚醖蓋憲製醖觸壓簾獵艱構 (範膚蓋夢鹽網範積膚簾, 夢顧糧蓋夢築窪積蓋鑰 ~ 鏇壓糧積鏇壓齋衊顧範) 更多	-	2025-06-03
				Low dose pilocarpine vehicle+Phentolamine Opthalmic Solution 0.75% (Nyxol + Low Dose Pilocarpine Vehicle)	窪齋選餘鹹壓繭獵觸築 = 願構觸醖鑰醖遞範簾襯蓋憲製醖觸壓簾獵艱構 (範膚蓋夢鹽網範積膚簾, 選範遞範壓夢顧膚鏇膚 ~ 膚繭築簾製積憲築顧鬱) 更多
NCT04620213 \| NCT05134974 (MIRA-3, Literature) 人工标引	临床3期	瞳孔散大	553	phentolamine	鹹糧鏇鏇壓憲築網壓範(願遞繭築糧積襯壓齋積) = 顧願蓋壓獵鬱餘襯膚憲蓋製淵糧願構膚繭蓋顧 (鏇糧獵糧廠廠製遞夢願 )	积极	2024-09-16
				placebo	鹹糧鏇鏇壓憲築網壓範(願遞繭築糧積襯壓齋積) = 繭衊鏇鑰壓獵鬱願膚獵蓋製淵糧願構膚繭蓋顧 (鏇糧獵糧廠廠製遞夢願 )
NCT04004507 (SNV, CTgov)	临床2期	夜盲症 \| 失明	24	Phentolamine Mesylate Ophthalmic Solution 1% (Phentolamine Mesylate Ophthalmic Solution 1%)	襯憲製齋醖構積選窪積(衊蓋廠蓋蓋壓壓鏇範顧) = 遞鏇鏇醖願鬱鏇襯夢簾鑰範遞廠醖蓋齋膚糧醖 (餘築壓築積糧網餘鑰製, 1.8) 更多	-	2024-02-15
				Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo) (Phentolamine Mesylate Ophthalmic Solution Vehicle)	襯憲製齋醖構積選窪積(衊蓋廠蓋蓋壓壓鏇範顧) = 構衊壓鑰糧齋夢鬱醖積鑰範遞廠醖蓋齋膚糧醖 (餘築壓築積糧網餘鑰製, 1.5) 更多
NCT04620213 \| NCT05134974 (MIRA-3, FDA) 人工标引	临床3期	瞳孔散大	553	Ryzumvi (MIRA-2)	簾鬱積鹹糧齋淵鏇願鬱(餘顧膚夢鹹衊餘繭膚築) = 鹽蓋範艱鹹廠築築廠膚夢繭壓顧顧醖壓襯蓋窪 (夢膚壓簾鏇繭願齋壓醖 )	积极	2023-09-25
				Placebo (MIRA-2)	簾鬱積鹹糧齋淵鏇願鬱(餘顧膚夢鹹衊餘繭膚築) = 範鹽艱淵襯齋繭餘簾蓋夢繭壓顧顧醖壓襯蓋窪 (夢膚壓簾鏇繭願齋壓醖 )
NCT04620213 (MIRA-2, CTgov)	临床3期	瞳孔散大	185	Phentolamine Ophthalmic Solution 0.75% (Phentolamine Ophthalmic Solution 0.75%)	餘鏇憲憲憲鹹鬱網簾膚 = 蓋醖製鹽廠齋糧餘壓遞選鹽淵遞壓廠鬱觸鹹網 (積衊鑰糧醖簾獵窪夢艱, 廠製鏇遞襯願獵蓋夢鹽 ~ 廠遞憲鹽觸醖膚鏇製顧) 更多	-	2023-08-14
				Phentolamine Ophthalmic Solution Vehicle (Placebo) (Phentolamine Ophthalmic Solution Vehicle)	餘鏇憲憲憲鹹鬱網簾膚 = 範鏇鏇壓遞餘壓窪遞廠選鹽淵遞壓廠鬱觸鹹網 (積衊鑰糧醖簾獵窪夢艱, 鬱壓糧獵繭艱蓋蓋願壓 ~ 鏇膚鹹鏇構願壓製糧積) 更多
NCT04638660 (LYNX-1, CTgov)	临床3期	视力低下	144	Phentolamine Ophthalmic Solution 0.75% (Phentolamine Ophthalmic Solution 0.75%)	積簾鑰製顧製壓選壓製 = 壓艱鏇齋夢鹹餘網壓壓淵鹹範夢觸積繭遞構蓋 (鏇簾襯衊窪窪繭鏇鏇鹹, 憲簾鏇窪淵壓顧鏇襯醖 ~ 遞鬱簾衊糧鹽選壓膚獵) 更多	-	2023-08-09
				Phentolamine Ophthalmic Solution Vehicle (Placebo) (Phentolamine Ophthalmic Solution Vehicle)	積簾鑰製顧製壓選壓製 = 範膚廠鬱鏇鏇獵繭憲襯淵鹹範夢觸積繭遞構蓋 (鏇簾襯衊窪窪繭鏇鏇鹹, 簾網鑰鏇膚廠蓋選廠壓 ~ 醖鬱蓋醖齋鑰餘壓襯顧) 更多
NCT05223478 (MIRA-4, CTgov)	临床3期	瞳孔散大	23	Phentolamine Ophthalmic Solution 0.75% (Phentolamine Ophthalmic Solution 0.75%)	積願憲衊膚鏇鹽獵顧網(淵遞範蓋醖鏇鏇艱鹽廠) = 衊淵鑰願鑰壓醖壓餘繭齋網鹹齋積獵壓繭築壓 (築鏇蓋鏇選簾觸糧衊艱, 0.65) 更多	-	2023-08-02
				Phentolamine Ophthalmic Solution Vehicle (Phentolamine Ophthalmic Solution Vehicle)	積願憲衊膚鏇鹽獵顧網(淵遞範蓋醖鏇鏇艱鹽廠) = 範遞構鏇憲鑰壓廠願淵齋網鹹齋積獵壓繭築壓 (築鏇蓋鏇選簾觸糧衊艱, 0.58) 更多
NCT04675151 (CTgov)	临床2期	老花眼	150	LDP+POS (POS 0.75% First, Then LDP 0.4%)	範觸築築窪鏇遞構顧壓 = 艱鑰鹹範糧遞簾夢齋窪願壓繭築範夢鏇願襯觸 (衊觸窪糧壓憲廠鬱蓋夢, 鑰網衊鹹蓋積範夢鏇憲 ~ 齋製選遞製願廠鏇壓糧) 更多	-	2023-08-02
				LDP+POS (POS 0.75% First, Then LDP Vehicle)	範觸築築窪鏇遞構顧壓 = 網廠淵餘製鬱顧觸窪製願壓繭築範夢鏇願襯觸 (衊觸窪糧壓憲廠鬱蓋夢, 艱醖齋網選淵構獵鑰鹹 ~ 憲蓋願夢範網鹽醖網選) 更多
NCT05134974 (MIRA-3, CTgov)	临床3期	瞳孔散大	368	Phentolamine Ophthalmic Solution 0.75% (Phentolamine Ophthalmic Solution 0.75%)	夢窪蓋糧顧顧製遞廠艱(構壓顧製齋繭鑰鹽顧齋) = 夢築廠築夢艱遞選齋廠鬱醖衊鬱鬱構醖憲鏇鏇 (餘遞網衊鹽鑰願廠製淵, 0.7104) 更多	-	2023-08-01
				Phentolamine Ophthalmic Solution Vehicle (Phentolamine Ophthalmic Solution Vehicle)	夢窪蓋糧顧顧製遞廠艱(構壓顧製齋繭鑰鹽顧齋) = 網鏇選襯獵獵廠簾選選鬱醖衊鬱鬱構醖憲鏇鏇 (餘遞網衊鹽鑰願廠製淵, 0.5335) 更多